HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development.
about
Overexpression of receptor for advanced glycation end products and high-mobility group box 1 in human dental pulp inflammation.Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.HMGB1 Promotes Intraoral Palatal Wound Healing through RAGE-Dependent Mechanisms.Anti-high mobility group box 1 antibody suppresses local inflammatory reaction and facilitates olfactory nerve recovery following injury.
P2860
HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
HMGB1 as a therapeutic target ...... for novel therapy development.
@en
HMGB1 as a therapeutic target ...... for novel therapy development.
@nl
type
label
HMGB1 as a therapeutic target ...... for novel therapy development.
@en
HMGB1 as a therapeutic target ...... for novel therapy development.
@nl
prefLabel
HMGB1 as a therapeutic target ...... for novel therapy development.
@en
HMGB1 as a therapeutic target ...... for novel therapy development.
@nl
P2093
P2860
P356
P1476
HMGB1 as a therapeutic target ...... for novel therapy development
@en
P2093
Chiemi Kikuchi
Hisaaki Uchikado
Kei Miyata
Kiyoshi Kikuchi
Ko-Ichi Kawahara
Naohisa Miyagi
Naoki Miura
Naoto Shiomi
Narumi Iida
Rokudai Sakamoto
P2860
P304
P356
10.3892/ETM.2011.310
P577
2011-06-30T00:00:00Z